Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection

Journal of General Virology

Volumn 77, Issue 12, 1996, Pages 3077-3085

  Roberts, M Luisa ^a,b   Luxembourg, Alain T ^a,c   Cooper, Neil R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; VIRUS RECEPTOR;

ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE INDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTION;

B-LYMPHOCYTES; GENE EXPRESSION; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; RECEPTORS, COMPLEMENT 3D; RECEPTORS, IGE; RECEPTORS, VIRUS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

HUMAN HERPESVIRUS 4;

EID: 0030463996     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-77-12-3077     Document Type: Article

References (51)

1. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M. & Fukami, Y. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. Journal of Biological Chemistry 262, 5592-5595.
2. Aquino, A., Lisi, A., Pozzi, D., Ravagnan, G. & Grimaldi, S. (1993). EBV membrane receptor (CR2) is phosphorylated by protein kinase C (PKC) in the early stages of virus entry into lymphoblastoid cells line (Raji). Biochemical and Biophysical Research Communications 196, 794-802.
3. Aubry, J.-P., Pochon, S., Graber, P., Jansen, K. U. & Bonnefoy, J.-Y. (1992). CD21 is a ligand for CD23 and regulates IgE production. Nature 358, 505-507.
4. Bohnsack, J. F. & Cooper, N. R. (1988). CR2 ligands modulate human B cell activation. Journal of Immunology 141, 2569-2576.
5. Carter, R. H., Tuveson, D. A., Park, D. J., Rhee, S. G. & Fearon, D. T. (1991). The CD19 complex of B lymphocytes: activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. Journal of Immunology 147, 3663-3671.
6. Cheung, R. K. & Dosch, H.-M. (1991). The tyrosine kinase lck is critically involved in the growth transformation of human B lymphocytes. Journal of Biological Chemistry 266, 8667-8670.
7. Chomczynski, P. & Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162, 156-159.
8. Cooper, N. R. (1994). Interactions of the complement system with microorganisms. In New Aspects of Complement Structure and function, pp. 133-149. Edited by A. Erdei. Austin: R. G. Landes Co.
9. Dosch, H.-M., Lam, P., Hui, M. F., Hibi, T. & Cheung, R. K. (1990). EBV utilizes a unique activation pathway for the transformation of human B cells. International Immunology 2, 833-848.
10. Dugas, B., Delfraissy, J.-F., Calenda, A., Peuchmaur, M., Wallon, C., Rannou, M.-T. & Galanaud, P. (1988). Activation and infection of B cells by Epstein-Barr virus. Journal of Immunology 141, 4344-4351.
11. Fearon, D. T. & Carter, R. H. (1995). The CD19/CR2/TAPA-1 complex of B lymphocytes : linking natural to acquired immunity. Annual Review of Immunology 13, 127-149.
12. Fukazawa, H., Li, P.-M., Yamamoto, C., Murakami, Y., Mizuno, S. & Uehara, Y. (1991). Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochemical Pharmacology 42, 1661-1671.
13. Gazit, A., Yaish, P., Gilon, C. & Levitzki, A. (1989). Tyrphostins. I. Synthesis and biological activity of protein tyrosine kinase inhibitors. Journal of Medical Chemistry 32, 2344-2352.
14. Gold, M. R. & DeFranco, A. L. (1994). Biochemistry of B lymphocyte activation. Advances in Immunology 55, 221-295.
15. Gopalakrishna, R., Chen, Z. H. & Gundimeda, U. (1992). Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C. FEBS Letters 314, 149-154.
16. Gordge, P. C. & Ryves, W. J. (1994). Inhibitors of protein kinase C. Cellular Signalling 6, 871-879.
17. Gordon, J., Walker, L., Guy, G., Brown, G., Rowe, M. & Rickinson, A. (1986). Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. Immunology 58, 591-595.
18. Guy, G. R. & Gordon, J. (1989). Epstein-Barr virus and a tumour-promoting phorbol ester use similar mechanisms in the stimulation of human B-cell proliferation. International Journal of Cancer 43, 703-708.
19. Hatzfeld, A., Fischer, E., Levesque, J. P., Perrin, R., Hatzfeld, J. & Kazatchkine, M. D. (1988). Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus positive human B cell line. Journal of Immunology 140, 170-175.
20. Hurley, E. A. & Thorley-Lawson, D. A. (1988). B cell activation and the establishment of Epstein-Barr virus latency. Journal of Experimental Medicine 168, 2059-2075.
21. Iwasaki, T., Uehara, Y., Graves, L., Rachie, N. & Bomsztyk, K. (1992). Herbimycin A blocks IL-1-induced NF-κB DNA-binding activity in lymphoid cell lines. FEBS Letters 298, 240-244.
22. Kobayashi, E., Nakano, H., Morimoto, M. & Tamaoki, T. (1989). Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochemical and Biophysical Research Communications 159, 548-553.
23. Liebowitz, D. & Kieff, E. (1993). Epstein-Barr Virus. In The Human Herpesviruses, pp. 107-172. Edited by B. Roizman, R. J. Whitley & C. Lopez. New York: Raven Press.
24. Liu, Y.-J., Cairns, J. A., Holder, M. J., Abbot, S. D., Jansen, K. U., Bonnefoy, J,-Y., Gordon, J. & MacLennan, C. M. (1991). Recombinant 25kDa CD23 and interleukin 1 alpha promote the survival of germinal centre B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. European Journal of Immunology 21, 1107-1114.
25. Luxembourg, A. T. & Cooper, N. R. (1994 a). T cell dependent B cell activating properties of antibody-coated small latex beads: a new model for B cell activation. Journal of Immunology 153, 604-614.
26. Luxembourg, A. T. & Cooper, N. R. (1994 b). Modulation of signalling via the B cell antigen receptor by CD21, the receptor for C3dg and Epstein-Barr virus. Journal of Immunology 153, 4448-4457.
27. Melchers, F., Erdei, A., Sthulz, T. & Dierich, M. P. (1985). Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 317, 264-267.
28. Misichak, H., Kolch, W., Goodnight, J., Davidson, W. F., Rapp, U., Rose-John, S. & Mushinski, J. F. (1991). Expression of protein kinase C genes in hemopoietic cells is cell-type and B cell-differentiation stage specific. Journal of Immunology 147, 3981-3987.
29. Nakanishi, H. & Exton, J. H. (1992). Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. Journal of Biological Chemistry 267, 16347-16354.
30. Nemerow, G. R. & Cooper, N. R. (1981). Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. Journal of Immunology 127, 272-278.
31. Nemerow, G. R. & Cooper, N. R. (1984 a). Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proceedings of the National Academy of Sciences, USA 81, 4955-4959.
32. Nemerow, G. R. & Cooper, N. R. (1984 b). Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology 132, 186-198.
33. Nemerow, G. R., Wolfert, R., McNaughton, M. E. & Cooper, N. R. (1985). Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor. Journal of Virology 55, 347-351.
34. Nemerow, G. R., Houghten, R. A., Moore, M. D. & Cooper, N. R. (1989). Identification of the epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56, 369-377.
35. Nemerow, G. R., Luxembourg, A. T. & Cooper, N. R. (1994). CD21/ CR2, its role in EBV infection and immune function. Epstein-Barr Reports 1, 59-64.
36. 1-positive leukemia cells. Leukemia and Lymphoma 12, 41-49.
37. Oudinet, J. P., Feliers, D. & Pavlovic-Hournac, M. (1992). Immunological identification of protein kinase C-α and protein kinase C-δ in cultured rat mesangial cells: differential sensitivity of the two isoforms towards the protein kinase inhibitor H7. Cellular Signalling 4, 559-569.
38. Rochford, R., Hobbs, M. V., Gamier, J.-L., Cooper, N. R. & Cannon, M. J. (1993). Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proceedings of the National Academy of Sciences, USA 90, 352-356.
39. Simpson, J., Johnson, M. S. & Mitchell, R. (1993). H7-resistant protein kinase C substrates in two-dimensional gels of proestrous rat anterior pituitary gland. Biochimica et Biophysica Acta 1220, 69-75.
40. Sinclair, A. J. & Farrell, P. J. (1995). Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. Journal of Virology 69, 5461-5468.
41. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO Journal 13, 3321-3328.
42. Takahashi, I., Kobayashi, E., Nakano, H., Murakata, C., Saitoh, H., Suzuki, K. & Tamaoki, T. (1990). Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C. Journal of Pharmacology and Experimental Therapeutics 255, 1218-1221.
43. Tanner, J., Weis, J., Fearon, D., Whang, Y. & Kieff, E. (1987). Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell 50, 203-213.
44. Tanner, J., Whang, Y., Sample, J., Sears, A. & Kieff, E. (1988). Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. Journal of Virology 62, 4452-4464.
45. Tanner, J. E., Alfieri, C., Chatila, T. A. & Diaz-Mitoma, F. (1996). Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220. Journal of Virology 70, 570-575.
46. Thorley-Lawson, D. A. & Mann, K. P. (1985). Early events in Epstein-Barr virus infection provide a model for B cell activation. Journal of Experimental Medicine 162, 45-59.
47. Thorley-Lawson, D. A., Nadler, L. M., Bhan, A. K. & Schooley, R. T. (1985). Blast-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein-Barr virus. Journal of Immunology 134, 3007-3012.
48. Uckun, F. M., Burkhardt, A. L., Jarvis, L., Jun, X., Stealey, B., Dibirdik, I., Myers, D. E., Tuel-Ahlgren, L. & Bolen, J. B. (1993). Signal transduction through the CD19 receptor during discrete development stages of human B-cell ontogeny. Journal of Biological Chemistry 268, 21172-21184.
49. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J. & Myers, D. E. (1995). Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267, 886-891.
50. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. & Kieff, E. (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. Journal of Virology 64, 2309-2318.
51. Wang, F., Kikutani, H., Tsang, S.-F., Kishimoto, T. & Kieff, E. (1991). Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. Journal of Virology 65, 4101-4106.